scPharmaceuticals (SCPH) Price & Analysis

Compare

― Followers

SCPH Stock Chart & Stats

$5.67

$0.00(0.00%)

Oct 06, 2025

―

Day’s RangeN/A

52-Week Range― - ―

Previous CloseN/A

VolumeN/A

Average Volume (3M)N/A

Market Cap

N/A

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

BetaN/A

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. VolumeN/A

30 Day Avg. VolumeN/A

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

Bulls Say, Bears Say

Bulls Say

Cost EfficiencyThe autoinjector could reduce costs associated with Furoscix by 70-75%, indicating potential for increased efficiency.

Market AcceptanceThe rapid adoption of Furoscix in chronic kidney disease among nephrologists suggests a strong market acceptance.

Revenue GrowthRevenue of $16.0M exceeded expectations, up 99.2% compared to the previous year.

Bears Say

Competitive InterestNo additional bidders are expected, suggesting limited competitive interest in acquiring scPharmaceuticals beyond the current agreement with MannKind.

Profitability LimitationThe company's ability to invest for growth was limited by the company's balance sheet and the need to achieve profitability.

Stock RecommendationAnalyst downgrades scPharmaceuticals shares to Hold from Buy, reflecting a cautious stance on future stock price appreciation.

scPharmaceuticals News

MannKind completes acquisition of scPharmaceuticals

MannKind (MNKD) Corporation completed the previously announced acquisition of scPharmaceuticals (SCPH). The acquisition of scPharmaceuticals is expected to...

12d ago

MNKD

SCPH

scPharmaceuticals Completes Merger and Delists from Nasdaq

The latest update is out from scPharmaceuticals ( ($SCPH) ). On October 7, 2025, scPharmaceuticals completed a merger...

12d ago

SCPH

scPharmaceuticals Issues Promissory Note to MannKind

The latest update is out from scPharmaceuticals ( ($SCPH) ). On September 23, 2025, scPharmaceuticals Inc. issued an...

24d ago

SCPH

Marvell downgraded, Dollar Tree upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

2M ago

AHL

SWX

scPharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright downgraded scPharmaceuticals (SCPH) to Neutral from Buy with a price target of $5.35, down from $18,...

2M ago

SCPH

scPharmaceuticals downgraded to Hold from Buy at Maxim

Maxim analyst Naz Rahman downgraded scPharmaceuticals (SCPH) to Hold from Buy after the company agreed to be acquired...

2M ago

MNKD

SCPH

MannKind price target raised to $8 from $7 at RBC Capital

RBC Capital analyst Douglas Miehm raised the firm’s price target on MannKind (MNKD) to $8 from $7 and...

2M ago

MNKD

SCPH

scPharmaceuticals downgraded to Hold from Buy at Craig-Hallum

Craig-Hallum downgraded scPharmaceuticals (SCPH) to Hold from Buy with a $6 price target after the company agreed to...

2M ago

SCPH

H.C. Wainwright positive on MannKind deal for scPharmaceuticals

H.C. Wainwright reiterates a Buy rating on MannKind (MNKD) with a $9 price target saying it views the...

2M ago

MNKD

SCPH

H.C. Wainwrights positive on MannKind deal for scPharmaceuticals

H.C. Wainwright reiterates a Buy rating on MannKind (MNKD) with a $9 price target saying it views the...

2M ago

MNKD

SCPH

scPharmaceuticals downgraded to Hold from Buy at Maxim

Maxim downgraded scPharmaceuticals (SCPH) to Hold from Buy after the company agreed to be acquired by MannKind (MNKD)...

2M ago

SCPH

Keurig Dr Pepper buys JDE Peet’s, Thoma Bravo to acquire Verint: Morning Buzz

The major averages were mixed near noon after a strong rally last Friday spurred by renewed optimism around...

2M ago

scPharmaceuticals Announces Merger with MannKind Corporation

The latest announcement is out from scPharmaceuticals ( ($SCPH) ). On August 24, 2025, scPharmaceuticals entered into a...

2M ago

SCPH

scPharmaceuticals Extends SmartDose Supply Agreement

scPharmaceuticals ( ($SCPH) ) just unveiled an announcement. On August 20, 2025, scPharmaceuticals Inc. amended its supply agreement...

2M ago

SCPH

SCPH FAQ

What was Scpharmaceuticals’s price range in the past 12 months?

Currently, no data Available

What is Scpharmaceuticals’s market cap?

Currently, no data Available

When is Scpharmaceuticals’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Scpharmaceuticals’s earnings last quarter?

Currently, no data Available

Is Scpharmaceuticals overvalued?

According to Wall Street analysts Scpharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Scpharmaceuticals pay dividends?

Scpharmaceuticals does not currently pay dividends.

What is Scpharmaceuticals’s EPS estimate?

Scpharmaceuticals’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Scpharmaceuticals have?

Currently, no data Available

What happened to Scpharmaceuticals’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Scpharmaceuticals?

Currently, no hedge funds are holding shares in SCPH

Company Description

Scpharmaceuticals

scPharmaceuticals Inc. is a biotechnology company focused on the development and commercialization of innovative pharmaceutical products that utilize its proprietary subcutaneous drug delivery technology. The company operates primarily in the healthcare sector, with a core focus on providing treatments for patients with chronic conditions, particularly in the areas of heart failure and other serious illnesses. scPharmaceuticals aims to enhance patient outcomes and improve the convenience of administering medications through its products, which include its lead product candidate, Furoscix, a subcutaneous formulation of furosemide for the treatment of worsening heart failure.